The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Provided herein are compositions, including products of manufacture such as formulations, and kits, and methods, for treatment, amelioration or prevention of a disease, infection or condition caused or exacerbated by a pathological or abnormal in situ microbiome space, or a gastrointestinal (GI), disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., by a pathological GI or colonic microbiome residing in a gut mucosa.

Provided herein are compositions, including products of manufacture such as formulations, and kits, and methods, for treatment, amelioration or prevention of a disease, infection or condition caused or exacerbated by a pathological or abnormal in situ microbiome space, or a gastrointestinal (GI), disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., by a pathological GI or colonic microbiome residing in a gut mucosa.

Methods of inhibiting or reducing tumor metabolism and growth are disclosed. A composition containing oxygen scavenging membrane fragments is administered within a tumor to create a hypoxic environment. This interferes with tumor growth and metabolism, and can lead to tumor death.

Methods of inhibiting or reducing tumor metabolism and growth are disclosed. A composition containing oxygen scavenging membrane fragments is administered within a tumor to create a hypoxic environment. This interferes with tumor growth and metabolism, and can lead to tumor death.

The present invention discloses a stable probiotic composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex.

The present invention discloses a stable probiotic composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprising Bacillus coagulans individually and/or in combination with multi-enzyme complex.

This disclosure relates to methods for obtaining immobilized enzyme preparations, in particular to a preparation and application of a novel active conjugate of an enzyme with a polymer carrier. Said conjugate possesses the properties of the known Longidaza® drug and inhibits hyperplasia of connective tissue, and presents anti-inflammatory action, and can be used for manufacturing stable, active and safe in use long-acting drugs in the form of a suppository, ointment, injection, cosmetic cream, and for making veterinary drugs. These methods include conjugation of hyaluronidase with a water-soluble copolymer using the carbodiimide or azide conjugation method. The conjugation is carried out with the use of a copolymer N-oxide 1,4-ethylene piperazine, (N carboxymethyl)-1,4-ethylene piperazine or its hydrazide, and 1,4-ethylene piperazine of general formula: ##STR00001## where n is from 40% to 90% of the total number of units; m is from 3% to 40% of the total number of units; and n+m+1=100%.

This disclosure relates to methods for obtaining immobilized enzyme preparations, in particular to a preparation and application of a novel active conjugate of an enzyme with a polymer carrier. Said conjugate possesses the properties of the known Longidaza® drug and inhibits hyperplasia of connective tissue, and presents anti-inflammatory action, and can be used for manufacturing stable, active and safe in use long-acting drugs in the form of a suppository, ointment, injection, cosmetic cream, and for making veterinary drugs. These methods include conjugation of hyaluronidase with a water-soluble copolymer using the carbodiimide or azide conjugation method. The conjugation is carried out with the use of a copolymer N-oxide 1,4-ethylene piperazine, (N carboxymethyl)-1,4-ethylene piperazine or its hydrazide, and 1,4-ethylene piperazine of general formula: ##STR00001## where n is from 40% to 90% of the total number of units; m is from 3% to 40% of the total number of units; and n+m+1=100%.